OPKO Health Inc
NASDAQ:OPK
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.8655
1.68
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
OPKO Health Inc
OPKO Health Inc
Income from Continuing Operations
OPKO Health Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OPKO Health Inc
NASDAQ:OPK
|
Income from Continuing Operations
-$133.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
13%
|
CAGR 10-Years
0%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$5.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$113m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-36%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$4.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
-$479.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4.7B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
17%
|
CAGR 10-Years
30%
|
|
OPKO Health Inc
Glance View
In the bustling world of healthcare and biotechnology, OPKO Health Inc. stands as a unique and dynamic player. Founded by the ambitious mind of Dr. Phillip Frost, the company has woven itself into the fabric of diverse biomedical sectors. OPKO predicates its enterprise on the integration of complementary businesses ranging from diagnostics to pharmaceuticals, creating synergies that are not just theoretical, but markedly operational. At the heart of its operations lies the interplay between new drug discovery and diagnostics development, allowing OPKO to leverage cutting-edge technologies in crafting novel health solutions. By honing in on significant medical unmet needs, they aspire to deliver innovations that address chronic diseases such as diabetes, oncology, and neurological disorders. This strategic weaving together of distinct healthcare sectors manifests in OPKO's sprawling portfolio—from the renowned Rayaldee, which targets secondary hyperparathyroidism, to its advanced diagnostics segments, which include proprietary tests for specific cancers and other conditions. The company's revenue streams can be best visualized as an interlocking lattice of healthcare services and products. It earns through a blend of product sales, licensing, and collaborative agreements with other biotech and pharmaceutical giants. Rayaldee, as a potent testament to their R&D prowess, contributes robustly to their revenue, while the diagnostics division, powered by their substantial investment in technology and infrastructure, brings in consistent sales from various testing services. The company’s BioReference Laboratories, one of the largest full-service diagnostic laboratories in the U.S., also plays a critical role in their financial architecture, offering both routine and esoteric tests. Additionally, OPKO is involved in strategic collaborations and licensing arrangements, enhancing its market footprint and creating channels for revenue infusion through partnerships with industry leaders. Ultimately, OPKO Health Inc.'s narrative is one of leveraging diversified capabilities and strategic partnerships to carve out a formidable presence in the complex landscape of global healthcare.
See Also
What is OPKO Health Inc's Income from Continuing Operations?
Income from Continuing Operations
-133.7m
USD
Based on the financial report for Sep 30, 2024, OPKO Health Inc's Income from Continuing Operations amounts to -133.7m USD.
What is OPKO Health Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
0%
Over the last year, the Income from Continuing Operations growth was 36%.
You don't have any saved screeners yet
